Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2026 | The future of AI in hematology: personalized medicine, opportunities and risks

Adrián Mosquera Orgueira • 24 Sep 2026
IMS 2026
General

Adrián Mosquera Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, discusses how artificial intelligence (AI) could transform hematology and oncology through integrated patient data analysis, personalized treatment selection, and earlier prediction of complications. He also highlights concerns around overreliance on AI in medical training, including the risk of reduced critical thinking and clinical skills among future physicians. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Adrián Mosquera Orgueira

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026
Combining isatuximab, lenalidomide, oral cyclophosphamide, & dexamethasone for HR smoldering myeloma
4:53
Combining isatuximab, lenalidomide, oral cyclophosphamide, & dexamethasone for HR smoldering myeloma
Maher Salamoon • 9 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals